The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal...

Area of Science:

• Gastroenterology
• Inflammatory Bowel Disease Research
• Clinical Therapeutics

Background:

• Mucosal healing (MH) is a key treatment target for ulcerative colitis (UC).
• The long-term implications and predictive factors for relapse after achieving MH in UC remain debated.
• Identifying predictors of relapse is crucial for refining UC management strategies.

Purpose of the Study:

• To evaluate clinical variables that predict relapse in ulcerative colitis patients after achieving mucosal healing.
• To establish a more precise therapeutic strategy for UC based on post-healing outcomes.

Main Methods:

• Retrospective analysis of 298 UC patients from April 2010 to February 2015.
• Mucosal healing defined as Mayo endoscopic subscore of 0 or 1.
• Kaplan-Meier analysis for cumulative relapse-free rates and Cox regression for predictive variable assessment.

Main Results:

• 29.5% of UC patients achieved MH; 23.9% of those relapsed.
• Cumulative relapse-free rates at 1, 3, and 5 years post-MH were 87.9%, 70.2%, and 63.8%, respectively.
• Use of an immunomodulator was identified as a significant predictor of relapse (P=0.035).

Conclusions:

• Endoscopic mucosal healing in UC patients is a significant prognostic indicator.
• UC refractoriness, indicated by the need for immunomodulators, influences long-term prognosis after MH.
• These findings support tailoring UC therapy based on individual patient responses and disease characteristics.